How We Got Here
Exenatide (Byetta) becomes the first GLP-1 approved for type 2 diabetes. Twice-daily injection, modest effects. Few noticed.
Semaglutide enters clinical trials. Early data shows unprecedented A1C reductions and unexpected weight loss in diabetes patients.
Wegovy (high-dose semaglutide) approved for obesity. 16.9% weight loss in STEP trials. Demand explodes. Shortages begin within months.
Tirzepatide (Mounjaro/Zepbound) approved. Dual GLP-1/GIP agonist achieves 22.5% weight loss. Celebrity use drives public awareness to fever pitch.
SELECT trial proves semaglutide reduces heart attacks and strokes by 20% — independent of weight loss. Game-changer for cardiologists.
Core semaglutide patent expires globally. Generics launch in India, China, Brazil. Orforglipron (first oral GLP-1 pill) gets FDA approval. Retatrutide Phase 3 shows 28.7% weight loss.
Why GLP-1s Work So Well
GLP-1 (glucagon-like peptide-1) is a natural hormone released by your gut after eating. It does four things:
- Stimulates insulin release — but only when blood glucose is high (avoiding dangerous hypoglycemia)
- Suppresses glucagon — the hormone that tells your liver to dump glucose into the blood
- Slows gastric emptying — food stays in your stomach longer, reducing post-meal glucose spikes
- Signals satiety to the brain — you feel full sooner and stay full longer
Synthetic GLP-1 agonists like semaglutide are engineered to last much longer than natural GLP-1 (which is destroyed within minutes). A single weekly injection provides continuous receptor activation for 7 days.
The Conditions GLP-1s Are Treating
Type 2 Diabetes
The original indication. Semaglutide lowers A1C by 1.5–2.0% — comparable to insulin but with weight loss instead of weight gain. It has become first-line therapy after metformin in most guidelines worldwide.
Obesity
The breakthrough application. At high doses, semaglutide (Wegovy) produces 15–17% weight loss; tirzepatide (Zepbound) achieves 20–23%. For context, lifestyle interventions alone average 3–5%, and older obesity drugs managed 5–10%.
Cardiovascular Disease
The SELECT trial (2024) proved semaglutide reduces major adverse cardiovascular events (heart attack, stroke, CV death) by 20% in overweight patients — even those without diabetes. This changed cardiology guidelines globally.
Liver Disease (MASH/NASH)
Non-alcoholic steatohepatitis affects 5% of adults globally. Semaglutide and survodutide are both showing dramatic liver fat reduction and fibrosis improvement in trials. This could become a $30+ billion market.
Chronic Kidney Disease
The FLOW trial showed semaglutide reduced kidney disease progression by 24% in diabetic patients. Nephrologists are now adding GLP-1s to standard of care.
Sleep Apnea
SURMOUNT-OSA showed tirzepatide reduced the apnea-hypopnea index by 50%+ in obese patients. Many patients were able to stop CPAP therapy.
The Access Crisis
Here's the uncomfortable truth: the GLP-1 revolution is happening primarily in wealthy countries.
| Country | Monthly Cost (Semaglutide) | Coverage |
|---|---|---|
| 🇺🇸 United States | $900–1,300 | Variable — many insurers exclude obesity indication |
| 🇬🇧 UK (NHS) | Free (if prescribed) | Limited — strict BMI + comorbidity criteria |
| 🇩🇪 Germany | €150–300 (with insurance) | Covered for diabetes; obesity pending |
| 🇮🇳 India (generic) | ₹2,000–4,000 ($24–48) | Out of pocket — no insurance coverage |
| 🇧🇷 Brazil (generic) | R$200–500 ($35–90) | Public system coverage limited |
| 🇳🇬 Nigeria | Not available | N/A |
The paradox: Diabetes and obesity burden is highest in low- and middle-income countries — but GLP-1 access is concentrated in high-income countries. The semaglutide patent expiry is beginning to change this, but coverage and distribution gaps remain massive.
What Patients Need to Know
They work — but they're not magic
GLP-1s are powerful, but they work best alongside lifestyle changes. Patients who combine medication with diet and exercise see 30–40% better outcomes than medication alone. And stopping the drug typically leads to significant weight regain — these are likely lifelong therapies for most.
Side effects are common but manageable
Nausea (30–40%), diarrhea (15–20%), and constipation (15%) are the most common side effects. They're worst during the first 4–8 weeks of dose titration and typically improve. Rare but serious risks include pancreatitis, gallbladder disease, and (in animal studies only) thyroid tumours.
The next generation is coming fast
If current GLP-1s don't work for you, or if you're waiting for oral options or better efficacy, the pipeline is rich. Read our guide to next-gen GLP-1 agonists — including retatrutide (28.7% weight loss), orforglipron (first oral pill), and CagriSema (amylin combo).
Generic access is expanding
If cost is a barrier, generic semaglutide is now available in India, Brazil, South Africa, and Canada at 70–85% lower prices. Read the full patent expiry guide for country-by-country timelines.
Start Your Diabetes Journey
Track medications, A1C, weight, and glucose — with AI-powered insights and personalised action plans.
Get Started Free →